PiTch Day: investors meet in the IZB
(f.l.t.r.) Dr. Georg Ried, Bayern Kapital, Dr. Karin Kleinhans, LSP, Philipp Hermannsdörfer, BayStartUp, Dr. Peter Hanns Zobel, Fördergesellschaft IZB mbH, Dr. Mathias Falcenberg, Forbion, Dr. Timothy Luker, Eli Lilly,Dr. Matthias Kromayer, MIG AG, Dr. Kreske Nickelsen, Coparion, Dr. Dirk Vocke, Merck KGaA, Dr. Christian Jung, Wellington Partners, Dr. Marianne Mertens, High-Tech Gründerfonds, Prof. Dr. Stefan Jaroch, Bayer AG, Dr. Klaus Mendla, Boehringer Ingelheim
Eight science teams give presentations at 3rd Munich Life Science Pitch Day at the IZB. Start-ups profit from being in close contact with the venture capital scene.
Auly 6 2017 – High-Tech Gründerfonds, Bayer Pharma AG, Merck KGaA and the Innovation and Start-up Center for Biotechnology (IZB) hosted the 3rd Munich Life Science Pitch Day at the IZB. Eight start-up teams had the opportunity to present their pioneering projects in front of 15 renowned venture capital and pharmaceutical companies. Among the prominent names taking part were MIG Fonds, Forbion Capital Partners, LSP Venture Capital, TVM Capital, Gimv, Biomed Partners, Bayern Kapital, Coparion, Vesalius Biocapital, Wellington Partners, Eli Lilly and Boehringer Ingelheim. The investors were impressed by the innovative ideas of the science teams as well as the consistently high level of quality of the presentations given. Dr. Marianne Mertens, Investment Manager in the Life Sciences team at High-Tech Gründerfonds, and Dr. Matthias Kromayer, Executive Board member at MIG AG, presided over the event.
Dr. Matthias Kromayer, CEO, MIG AG,
Prof. Dr. Armin Giese, Center for Neuropathology and Prion Research of the LMU
(f.l.t.r.) Dr. Marianne Mertens, Investment Manager, High-Tech Gründerfonds, Dr. Alexandra Goll, Senior Advisor, TVM Capital
“We are delighted that through the Life Science Pitch Day, we have created a platform that supports start-ups in finding suitable investors. Furthermore, in hosting the Asset Lounge for the first time we are looking to bring together entrepreneurs and technologies with the aim of implementing innovative ideas and developments. Together with strong partners from the venture capital sector and industry, we are hoping to put companies with high potential on the right track and lead them to success,” says Dr. Marianne Mertens.
Prof. Dr. Stefan Jaroch, Head of External Innovation Technologies at Bayer Pharma AG, is a partner of the event for the third time: “At the Pitch Day, we are seeking to initiate a dialogue with young entrepreneurs and investors in the life sciences sector. This complements our activities as an investor in High-Tech Gründerfonds and in managing the Co-Laborator incubators in San Francisco and Berlin. We are looking to foster an exchange of ideas while offering our expertise,” explains Jaroch.
Dr. Peter Hanns Zobel, IZB mbH,
Florian Hahn, MdB
Dr. Klaus Mendla, Global Head, CNS Business Development and Licensing, Boehringer Ingelheim
“Eli Lilly are looking to discover and partner with the best biomedical innovations at an increasingly early stage and events like this are very helpful in realising these goals.“
Dr. Tim Luker, Senior Director,
Emerging Technology & Innovation, Eli Lilly